Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes

Arterioscler Thromb Vasc Biol. 2023 Oct;43(10):2075-2077. doi: 10.1161/ATVBAHA.123.319748. Epub 2023 Aug 17.

Authors

Affiliations

¹ Division of Cardiovascular Medicine and Cardiovascular Institute (M.N.W., L.C.T., A.Q., I.J., S.V.C.-A., P.Q., Y.Y., K.M., X.W.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
² Department of Bioengineering, University of Pennsylvania, Philadelphia (M.N.W.).
³ Division of Infectious Diseases (M.-G.A.), Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

PMID: 37589141
PMCID: PMC10538392 (available on 2024-10-01)
DOI: 10.1161/ATVBAHA.123.319748

No abstract available

Keywords: cardiovascular diseases; cholesterol; epigenome; gene editing; lipoprotein.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

CRISPR-Cas Systems
Cardiovascular Diseases* / genetics
Cardiovascular Diseases* / therapy
DNA Methylation
Epigenesis, Genetic
Epigenome*
Gene Editing
Humans

Grants and funding